Icatibant

What is Icatibant?

Icatibant is a synthetic 10-amino-acid peptide (containing five non-proteinogenic amino acid substitutions for peptidase resistance) that acts as a selective, competitive antagonist at the bradykinin B2 receptor. It is FDA-approved (August 2011) under the brand name Firazyr — originally developed by Jerini, later Shire, now Takeda — for subcutaneous self-administered treatment of acute hereditary angioedema (HAE) attacks in adults 18 years and older. HAE attacks are driven by uncontrolled bradykinin generation: patients with C1-inhibitor deficiency cannot restrain plasma kallikrein, which cleaves high-molecular-weight kininogen to generate excess bradykinin, which in turn engages the B2 receptor on vascular endothelium to produce the disease's characteristic permeability and swelling. Icatibant blocks bradykinin at that terminal step, interrupting the downstream vasoactive effect regardless of how much bradykinin the contact system has produced.

What Icatibant Is Investigated For

Icatibant is FDA-approved as on-demand therapy for acute HAE attacks in adults, with the strongest evidence coming from the three pivotal For Angioedema Subcutaneous Treatment trials (FAST-1 vs. placebo, FAST-2 vs. tranexamic acid, FAST-3 vs. placebo). FAST-3 was the confirmatory trial for the US label: a single 30 mg subcutaneous injection produced median time to ≥50% symptom reduction of 2.0 hours vs. 19.8 hours on placebo (p<0.001), with onset of primary symptom relief at 1.5 hours vs. 18.5 hours. FAST-2 showed a similar separation (2.0 hours vs. 12.0 hours) against an active comparator. Efficacy across cutaneous, abdominal, and laryngeal HAE attacks is consistent in trial and real-world Icatibant Outcome Survey (IOS) data, and the self-injection format is a key practical advantage — roughly 9 of 10 trial attacks resolved with a single dose. The honest caveats are specific. Off-label use in ACE-inhibitor-induced angioedema produced an early positive Phase 2 signal but a subsequent larger Phase 3 trial and a meta-analysis did not confirm superiority over placebo or standard care, so the evidence for that indication is mixed at best. Injection-site reactions (erythema, wheal, burning, itching) occur in essentially all patients but are self-limited. Icatibant does not prevent HAE attacks — it treats them; long-term prophylaxis is a different drug class (C1-INH replacement, lanadelumab, berotralstat). And despite the molecule's broad theoretical relevance to bradykinin-driven conditions (sepsis, pancreatitis, COVID-related pulmonary edema), off-label and investigational indications outside HAE remain poorly validated.

History & Discovery

Icatibant originated in the early 1990s at Hoechst AG (later Aventis, then Sanofi-Aventis) as compound HOE 140, developed in a medicinal chemistry program aimed at producing a peptidase-resistant, purely antagonist bradykinin B2 receptor ligand. Earlier-generation bradykinin antagonists had retained partial agonist activity (notably on the guinea-pig trachea), which limited their therapeutic use; HOE 140 was the first agent in its class to behave as a clean antagonist with in vivo stability suitable for subcutaneous dosing. The key design move was substitution of five non-proteinogenic amino acid residues (including D-amino acids and the conformationally constrained residues Hyp, Thi, D-Tic, and Oic) into the bradykinin scaffold — producing a decapeptide that bound B2 with high affinity while resisting hydrolysis by the peptidases that would destroy bradykinin itself. Early clinical development explored a broad range of bradykinin-implicated conditions including asthma, rhinitis, and traumatic brain injury, with mixed or disappointing results. The program was acquired by Jerini AG (a Berlin-based biotech), which refocused development on hereditary angioedema — an indication where the mechanistic rationale was particularly clean because HAE is a directly bradykinin-mediated disease. Jerini ran the pivotal For Angioedema Subcutaneous Treatment (FAST) program: FAST-1 (vs. placebo) and FAST-2 (vs. oral tranexamic acid) were the NEJM-published Phase 3 trials; FAST-3 (vs. placebo) was the confirmatory US-regulatory Phase 3. FAST-2 and FAST-3 both met primary endpoints; FAST-1 narrowly missed its primary endpoint but supported the overall efficacy conclusion. Icatibant was approved in the EU in 2008 under the brand name Firazyr. Shire acquired Jerini in 2008, and icatibant subsequently became part of Shire's HAE franchise. The FDA approved Firazyr in August 2011 based on the FAST program. Shire was acquired by Takeda in 2019, bringing icatibant into the Takeda rare-disease portfolio, where it remains a core on-demand option for HAE alongside the broader HAE armamentarium that has since expanded to include long-term kallikrein-inhibitor prophylaxis (lanadelumab, berotralstat) and C1-INH replacement (Cinryze, Berinert, Haegarda). Generic icatibant has become available in various markets following patent expirations. Off-label investigation continued along bradykinin-adjacent lines — ACE-inhibitor-induced angioedema (mixed evidence, described in more detail below), acquired C1-inhibitor deficiency, and during the early COVID-19 pandemic a handful of trials evaluated icatibant for bradykinin-storm-mediated pulmonary edema, with no indication change emerging from that work. Icatibant remains one of the cleaner single-receptor-antagonist drug stories in rare disease: a mechanism-targeted peptide, with a specific indication and a durable real-world safety profile across more than a decade of post-marketing experience.

How It Works

An HAE attack happens when the body makes too much bradykinin — a small signaling peptide that tells blood vessels to leak fluid, causing the characteristic swelling. Icatibant is a decoy that sits on the bradykinin receptor and blocks bradykinin from binding. The 'leak' signal gets cut off, and the attack resolves within hours.

Icatibant is a synthetic decapeptide (D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg) containing five non-proteinogenic amino acid residues that confer resistance to plasma and tissue peptidases — notably carboxypeptidase M/N and angiotensin-converting enzyme — which would otherwise degrade a native bradykinin-based peptide rapidly. This gives icatibant a plasma half-life of approximately 1.4 hours, long enough for a single subcutaneous dose to cover the typical onset-and-progression window of an HAE attack. Mechanistically, icatibant is a selective, competitive, surmountable antagonist at the B2 bradykinin receptor, with no significant agonist activity at the receptor (distinguishing it from earlier first-generation bradykinin antagonists, which retained partial agonist activity at the guinea-pig trachea). It has comparatively minor activity at the B1 receptor. In HAE pathophysiology, C1-inhibitor deficiency (type I — reduced C1-INH protein; type II — dysfunctional C1-INH) removes restraint on plasma kallikrein activation via the contact system. Unopposed kallikrein cleaves high-molecular-weight kininogen to release bradykinin. Bradykinin binds the constitutively expressed B2 receptor on vascular endothelial cells, activating Gq-coupled signaling, increasing intracellular calcium, inducing endothelial nitric oxide release and phosphorylation of endothelial junction proteins, and producing the transient increase in vascular permeability that manifests as HAE angioedema. Icatibant occupies the B2 receptor and prevents bradykinin-mediated activation regardless of circulating bradykinin concentration — the defining advantage of receptor antagonism over upstream kallikrein inhibition or C1-INH replacement in the setting of an ongoing attack. Notably, icatibant has also been reported to inhibit aminopeptidase N at micromolar concentrations (an off-target effect relevant to interpreting in vitro studies but not at therapeutic plasma concentrations). The mechanistic story for HAE is unusually clean: the disease is bradykinin-driven at a single, well-characterized receptor, and icatibant is the specific, receptor-level antagonist of that pathway.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Icatibant:

• 01ACE-inhibitor-induced angioedema — mixed evidence across Phase 2 and Phase 3 trials means the role of icatibant in this common and sometimes life-threatening condition remains unresolved; whether subpopulations (early administration, airway involvement, non-responders to standard therapy) benefit more is not defined.
• 02Pregnancy and lactation safety — published human experience is limited to case reports and small series; systematic pregnancy-outcome registries would clarify whether the reassuring signal in current data holds at scale.
• 03Acute cardiovascular ischemia — B2 antagonism in patients with acute coronary syndromes, recent stroke, or heart failure has not been adequately studied, and the theoretical concern that blocking cardioprotective bradykinin signaling could worsen ischemic injury is not empirically addressed.
• 04Pediatric long-term safety — approval in children age 2 and older (EU) and growing US pediatric experience is reassuring but follow-up horizons are limited; effects of repeated on-demand dosing across childhood and adolescence are still accruing.
• 05Bradykinin-mediated conditions beyond HAE — sepsis-related capillary leak, acute pancreatitis, traumatic brain injury, and COVID-19 pulmonary edema all have mechanistic rationale for bradykinin involvement, but none have produced a convincing efficacy signal in human trials with icatibant.
• 06Combination therapy with long-term prophylactics — how icatibant performs as breakthrough rescue in patients already on lanadelumab, berotralstat, or C1-INH replacement (a common real-world scenario) has been characterized descriptively but not systematically optimized.

Forms & Administration

Icatibant is supplied as a clear, colorless solution in a pre-filled single-dose syringe delivering 30 mg in 3 mL (10 mg/mL) for subcutaneous injection, typically into the abdominal area. The approved adult dose is 30 mg administered at the onset of an HAE attack; if symptoms persist or recur, a repeat 30 mg dose may be given after at least 6 hours, with no more than three doses in 24 hours. Patients with laryngeal attacks must seek emergency medical attention after injection — self-administration is not a substitute for hospital evaluation in airway-threatening events. All injectable peptides should only be administered under the guidance of a qualified healthcare provider; initial training for self-administration is part of the Firazyr prescribing workflow.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Icatibant is FDA-approved only as on-demand treatment for acute HAE attacks in adults. Use in other forms of angioedema (ACE-inhibitor-induced, idiopathic, histamine-mediated allergic) is off-label and not supported by consistent clinical-trial evidence. It does not prevent HAE attacks and does not replace long-term prophylactic therapy in patients with frequent attacks.

Timeline of Effects

Common Questions

Who Icatibant Is NOT For

Drug & Supplement Interactions

Icatibant is a peptide eliminated predominantly by proteolytic peptidase degradation rather than by cytochrome P450 pathways; clinically meaningful pharmacokinetic drug-drug interactions mediated by CYP enzymes are not expected, and no dose adjustment is required for CYP inducers or inhibitors. The most clinically relevant interaction involves angiotensin-converting enzyme (ACE) inhibitors and related renin-angiotensin-system drugs. ACE degrades bradykinin; co-administration of an ACE inhibitor increases endogenous bradykinin tone and, theoretically, could alter the balance of B2 receptor occupancy. In the specific clinical context of ACE-inhibitor-induced angioedema, an early positive Phase 2 trial and subsequent negative Phase 3 produced mixed evidence for icatibant as therapy — this is a clinical rather than a PK interaction, but it is the interaction most frequently asked about. Patients with HAE who also take ACE inhibitors should typically have the ACE inhibitor reconsidered, because ACE inhibitors can themselves precipitate HAE-like attacks and may increase baseline bradykinin tone. Pharmacodynamic considerations include co-administration with other agents that modulate vascular tone or coagulation-contact-system activity (other HAE-specific agents — C1-INH concentrate, ecallantide, lanadelumab — are not studied in simultaneous combination with icatibant for the same attack, and co-administration is not an established practice). Broad-spectrum peptidase inhibitors (e.g., aprotinin in investigational settings) could theoretically prolong icatibant exposure but are not a practical concern in routine HAE care. As with any prescription therapy, patients should disclose all concurrent medications, supplements, and relevant medical conditions to the prescribing clinician, and the official prescribing information should be the operative reference for specific interaction guidance.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions